132
The pressure is also increasing in Germany: the Zepbound weight loss syringe from the US manufacturer Eli Lilly has been available for prescription in this country for a few weeks now. In order to meet the expected demand, the Americans are even building a plant in Alzey in Rhineland-Palatinate for 2.3 billion euros. According to study data, patients who took Zepbound for 72 weeks were able to reduce their weight by 22.5 percent – the comparable values for Novo Nordisk are slightly lower. However, the Danes can still benefit from being the first on the market: The experts at pharmaceutical market researcher Global Data expect Zepbound sales of $4.1 billion for 2031, while Wegovy from Novo Nordisk is expected to reach $8.1 billion .